EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Fluorodeoxyglucose (FDG) PET/CT imaging analysis and clinical treatment evaluation in patients with SMARCA4-deficient tumors: case reports of four patients

Xueqin Zhao, Wei Fu

Journal of Cancer Research and Clinical Oncology · 2025

DOI: 10.1007/s00432-025-06207-9 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2025. Verfasst von Xueqin Zhao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Le Qun Road No.15, XiuFeng District, Guilin, 541000, Guan…. Hauptthemen laut MEDLINE: DNA Helicases, Fluorodeoxyglucose F18, Lung Neoplasms, Nuclear Proteins. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangxi Zhuang Autonomous Region Health Department.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aims to characterize SMARCA4-deficient tumors using 18F-FDG PET/CT and explore its role in diagnosis, staging, therapeutic response assessment, and prognosis across multiple pathological subtypes. METHODS: We retrospectively analyzed four patients with histologically confirmed SMARCA4-deficient tumors. Clinical features, 18F-FDG PET/CT findings, pathological subtypes, molecular characteristics, treatment modalities, and outcomes were evaluated. RESULTS: All tumors demonstrated high FDG uptake, indicating elevated metabolic activity. Imaging patterns varied by subtype, including undifferentiated carcinoma and non-small cell lung cancer. Treatment strategies involved chemotherapy, immunotherapy, and targeted therapy with diverse responses. SMARCA4 deficiency was associated with poor prognosis and potential treatment resistance. CONCLUSION: 18F-FDG PET/CT is valuable in the comprehensive assessment of SMARCA4-deficient tumors. Combined with molecular profiling, it enhances diagnostic accuracy and aids in individualized treatment planning. This case series offers preliminary guidance for clinicians managing this rare, aggressive tumor type.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA HelicasesFluorodeoxyglucose F18Lung NeoplasmsNuclear ProteinsPositron Emission Tomography Computed TomographyTranscription FactorsHumansPrognosisRadiopharmaceuticalsRetrospective Studies

Stichwörter der Autor:innen

18F-FDGPET/CTPathological subtypesSMARCA 4Treatment

Substanzen

DNA HelicasesFluorodeoxyglucose F18Nuclear ProteinsRadiopharmaceuticalsSMARCA4 protein, humanTranscription Factors

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Le Qun Road No.15, XiuFeng District, Guilin, 541000, Guangxi, China.
  • Department of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Le Qun Road No.15, XiuFeng District, Guilin, 541000, Guangxi, China. 13977385850@126.com.

Förderung

  • Guangxi Zhuang Autonomous Region Health Department

Zitieren

APA

Zhao, X., & Fu, W. (2025). Fluorodeoxyglucose (FDG) PET/CT imaging analysis and clinical treatment evaluation in patients with SMARCA4-deficient tumors: case reports of four patients. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-025-06207-9

Vancouver

Zhao X, Fu W. Fluorodeoxyglucose (FDG) PET/CT imaging analysis and clinical treatment evaluation in patients with SMARCA4-deficient tumors: case reports of four patients. Journal of Cancer Research and Clinical Oncology. 2025. doi:10.1007/s00432-025-06207-9

BibTeX
@article{Zhao2025,
  author = {Zhao, Xueqin and Fu, Wei},
  title = {Fluorodeoxyglucose (FDG) PET/CT imaging analysis and clinical treatment evaluation in patients with SMARCA4-deficient tumors: case reports of four patients},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2025},
  doi = {10.1007/s00432-025-06207-9}
}
Kostenlos starten →